单克隆抗体BDI－I导向的阿霉素白蛋白毫微球对人膀胱癌细胞的特异杀伤活性  

STUDY ON THE SPECIFIC KILLING ACTIVITY OF ALBUMMIN NANOPARTICLES CONTAINING ADRIAMYCIN TARGETED BY MONOCLONAL ANTIBODY BDI-1TO HUMAN BLADDER CANCER CELLS

作　　者：盛洁[1] 山登布卡 谢蜀生[1] 魏树礼[1] 

机构地区：[1]北京医科大学药剂学教研室,北京免疫学教研室

出　　处：《药学学报》1995年第9期706-710,共5页Acta Pharmaceutica Sinica

摘　　要：用化学偶联法将抗人膀胱癌单克隆抗体分子偶联到阿霉素白蛋白毫微球上，构建了一个有靶向杀伤性的免疫毫微球，即：阿霉素白蛋白载单克隆抗体毫微球（ＡＤＲ－ＮＰ－Ａｂ）。改变阿霉素毫微球和单克隆抗体的反应分子比，确定了制备该免疫毫微球的最佳条件。经免疫荧光检测及显微照像分析证明，免疫毫微球可有效地和人膀胱癌细胞结合。体外杀伤试验表明，此免疫毫微球对靶细胞ＥＪ有高度特异杀伤活性，而对无关的人直肠癌Ｌｏｖｏ细胞则无明显作用。A highly specific immuno- nanoparticle(ADR-NP-Ab)has been constituted bychemically coupling a monoclonal antibody BDI-1 to albumin nanoparticle containing adriamycin(ADR-NP).Different molecular ratios of antibedy to ADR-NP were tried to determine the optimalcondition for preparing the immuno- nanoparticle. The results of immunoflurecence and micropho-tographic analysis showed that the activity of ADR-NP-Ab was well preserved. The result of thecytotoxicity cytotoxicity of ADR-NP-Ab in vitro assay showed strong killing activity of ADR-NP-Ab to bladdercancer cells(EJ) ,while no apparent cytotoxlc activity to non-targeted human colon carcinoma cells(Lovo)was observed.

关 键 词：毫微球 单克隆抗体 阿霉素 膀胱肿瘤 白蛋白 

分 类 号：R73-361[医药卫生—肿瘤] R737.14[医药卫生—临床医学]